SCHEMBL2481768

SCHEMBL2481768

O=S(=O)(Nc1cccc(-c2nn3c(c2-c2ccncc2)SCCC3)c1)c1cccnc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 1/20 0.48
MAP2K4 P45985 3/20 0.45
MAP2K7 O14733 2/20 0.45
KMT2A Q03164 2/20 0.42
POLB P06746 1/20 0.39
HSD17B1 P14061 2/20 0.39
HSD17B2 P37059 2/20 0.39
PARP1 P09874 1/20 0.38
AURKA O14965 1/20 0.37
GAA P10253 2/20 0.36
TSHR P16473 1/20 0.36
LMNA P02545 2/20 0.36
TP53 P04637 1/20 0.36
THRB P10828 1/20 0.36
PRF1 P14222 1/20 0.36
CYP11B1 P15538 1/20 0.36
CYP11B2 P19099 1/20 0.36
CKS1B P61024 1/20 0.36
SKP2 Q13309 1/20 0.36
PDE4A P27815 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2479625 0.89 TP53 (0.47) MAP2K4MAP2K7KMT2APOLBHSD17B1
SCHEMBL2480518 0.88 POLB (0.39) BRD4KMT2APOLBGAALMNA
SCHEMBL15005451 0.85 MAPT (0.50) BRD4KMT2AHSD17B1HSD17B2GAA
SCHEMBL2478717 0.83 SYK (0.37) KMT2APOLBPARP1GAALMNA
SCHEMBL2479785 0.83 TP53 (0.46) MAP2K4MAP2K7KMT2APOLBHSD17B1
SCHEMBL2479611 0.82 TAAR1 (0.43) KMT2ATSHRLMNATP53MEN1
SCHEMBL2477800 0.82 LMNA (0.49) MAP2K4MAP2K7POLBLMNATP53
SCHEMBL2478590 0.81 KMT2A (0.49) BRD4KMT2AAURKATP53MEN1
SCHEMBL2477619 0.78 LMNA (0.45) POLBHSD17B1HSD17B2LMNATP53
SCHEMBL2477817 0.77 LMNA (0.42) KMT2AAURKAGAALMNATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8524707-B2 Bicyclic pyrazoles as protein kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2013-09-03 US disclosed
US-8524707-B2 Bicyclic pyrazoles as protein kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2013-09-03 US disclosed
EP-2373664-B1 BICYCLIC PYRAZOLES AS PROTEIN KINASE INHIBITORS NERVIANO MEDICAL SCIENCES SRL (IT) 2013-06-12 EP disclosed
US-20110257165-A1 BICYCLIC PYRAZOLES AS PROTEIN KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2011-10-20 US disclosed
US-20110257165-A1 BICYCLIC PYRAZOLES AS PROTEIN KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2011-10-20 US disclosed
US-20110257165-A1 BICYCLIC PYRAZOLES AS PROTEIN KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2011-10-20 US disclosed
EP-2373664-A1 BICYCLIC PYRAZOLES AS PROTEIN KINASE INHIBITORS Nerviano Medical Sciences S.r.l. (IT) 2011-10-12 EP disclosed
WO-2010070060-A1 BICYCLIC PYRAZOLES AS PROTEIN KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2010-06-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110257165-A1 BICYCLIC PYRAZOLES AS PROTEIN KINASE INHIBITORS MAP3K19, MAP4K3, MAP3K15 BRD4 377/4885MAP2K4 132/4885MAP2K7 91/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.